Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling

Neurobiology of Disease

Volumn 70, Issue , 2014, Pages 53-68

  Fuchs, Claudia ^a   Trazzi, Stefania ^a   Torricella, Roberta ^a   Viggiano, Rocchina ^a   De Franceschi, Marianna ^a   Amendola, Elena ^b   Gross, Cornelius ^b   Calzà, Laura ^a   Bartesaghi, Renata ^a   Ciani, Elisabetta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

Author keywords

AKT GSK 3 signaling; CDKL5 disorder; Dendritic development; Neurodevelopmental disorders; Neurogenesis impairment; Rett's syndrome

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; CDKL5 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE LIKE 5 GENE; DENDRITE; DENTATE GYRUS; FEMALE; GRANULE CELL; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL GROWTH; NEURAL STEM CELL; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPATIAL MEMORY; WORKING MEMORY; Y-MAZE TEST; ANIMAL MODEL; CDKL5 GENE; CELL COUNT; CELL DIFFERENTIATION; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE; GENE FUNCTION; HYPERTROPHY; LOSS OF FUNCTION MUTATION; NERVE CELL DIFFERENTIATION; PHENOTYPE; SURVIVAL RATE; WILD TYPE; ANIMAL; CELL CULTURE; CELL ENLARGEMENT; DEFICIENCY; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; MAZE TEST; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL ENLARGEMENT; CELL SURVIVAL; CELLS, CULTURED; DENDRITES; DENTATE GYRUS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; MALE; MAZE LEARNING; MICE, KNOCKOUT; NEURAL STEM CELLS; NEUROGENESIS; NEURONS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84903885705     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.06.006     Document Type: Article

References (57)

1. Aimone J.B., Deng W., Gage F.H. Adult neurogenesis: integrating theories and separating functions. Trends Cogn. Sci. 2010, 14:325-337.
2. Amendola E., Zhan Y., Mattucci C., Castroflorio E., Calcagno E., Fuchs C., Lonetti G., Silingardi D., Farley D., Ciani E., Pizzorusso T., Giustetto M., Gross C.T. Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS One 2014, 16(9(5)):e91613.
3. Armstrong D.D., Dunn J.K., Schultz R.J., Herbert D.A., Glaze D.G., Motil K.J. Organ growth in Rett syndrome: a postmortem examination analysis. Pediatr. Neurol. 1999, 20:125-129.
4. Bahi-Buisson N., Kaminska A., Boddaert N., Rio M., Afenjar A., Gerard M., Giuliano F., Motte J., Heron D., Morel M.A., Plouin P., Richelme C., des Portes V., Dulac O., Philippe C., Chiron C., Nabbout R., Bienvenu T. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia 2008, 49:1027-1037.
5. Bahi-Buisson N., Nectoux J., Rosas-Vargas H., Milh M., Boddaert N., Girard B., Cances C., Ville D., Afenjar A., Rio M., Heron D., N'Guyen Morel M.A., Arzimanoglou A., Philippe C., Jonveaux P., Chelly J., Bienvenu T. Key clinical features to identify girls with CDKL5 mutations. Brain 2008, 131:2647-2661.
6. Bahi-Buisson N., Villeneuve N., Caietta E., Jacquette A., Maurey H., Matthijs G., Van Esch H., Delahaye A., Moncla A., Milh M., Zufferey F., Diebold B., Bienvenu T. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am. J. Med. Genet. A 2012, 158A:1612-1619.
7. Belichenko N.P., Belichenko P.V., Li H.H., Mobley W.C., Francke U. Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J. Comp. Neurol. 2008, 508:184-195.
8. Belichenko N.P., Belichenko P.V., Mobley W.C. Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol. Dis. 2009, 34:71-77.
9. Bertani I., Rusconi L., Bolognese F., Forlani G., Conca B., De Monte L., Badaracco G., Landsberger N., Kilstrup-Nielsen C. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J. Biol. Chem. 2006, 281:32048-32056.
10. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
11. Biebl M., Cooper C.M., Winkler J., Kuhn H.G. Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain. Neurosci. Lett. 2000, 291:17-20.
12. Castilla-Ortega E., Pedraza C., Estivill-Torrus G., Santin L.J. When is adult hippocampal neurogenesis necessary for learning? evidence from animal research. Rev. Neurosci. 2011, 22:267-283.
13. Cheadle J.P., Gill H., Fleming N., Maynard J., Kerr A., Leonard H., Krawczak M., Cooper D.N., Lynch S., Thomas N., Hughes H., Hulten M., Ravine D., Sampson J.R., Clarke A. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum. Mol. Genet. 2000, 9:1119-1129.
14. Chen Q., Zhu Y.C., Yu J., Miao S., Zheng J., Xu L., Zhou Y., Li D., Zhang C., Tao J., Xiong Z.Q. CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J. Neurosci. 2010, 30:12777-12786.
15. Cole A.R. GSK3 as a sensor determining cell fate in the brain. Front. Mol. Neurosci. 2012, 10.3389/fnmol.2012.00004.
16. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
17. Contestabile A., Fila T., Bartesaghi R., Ciani E. Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol. 2009, 19:224-237.
18. Eom T.Y., Roth K.A., Jope R.S. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J. Biol. Chem. 2007, 282:22856-22864.
19. Evans J.C., Archer H.L., Colley J.P., Ravn K., Nielsen J.B., Kerr A., Williams E., Christodoulou J., Gecz J., Jardine P.E., Wright M.J., Pilz D.T., Lazarou L., Cooper D.N., Sampson J.R., Butler R., Whatley S.D., Clarke A.J. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur. J. Hum. Genet. 2005, 13:1113-1120.
20. Goto T., Monk M. Regulation of X-chromosome inactivation in development in mice and humans. Microbiol. Mol. Biol. Rev. 1998, 62:362-378.
21. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 2001, 78:1219-1232.
22. Guerrini R., Parrini E. Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies. Epilepsia 2012, 53:2067-2078.
23. Hou J.G., Xue J.J., Lee M.R., Sun M.Q., Zhao X.H., Zheng Y.N., Sung C.K. Compound K is able to ameliorate the impaired cognitive function and hippocampal neurogenesis following chemotherapy treatment. Biochem. Biophys. Res. Commun. 2013, 436:104-109.
24. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 2003, 24:441-443.
25. Jun H., Mohammed Qasim Hussaini S., Rigby M.J., Jang M.H. Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders. Neural Plast. 2012, 854285.
26. Kameshita I., Sekiguchi M., Hamasaki D., Sugiyama Y., Hatano N., Suetake I., Tajima S., Sueyoshi N. Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1. Biochem. Biophys. Res. Commun. 2008, 377:1162-1167.
27. Kang H.J., Noh J.S., Bae Y.S., Gwag B.J. Calcium-dependent prevention of neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase and phospholipase Cgamma. Mol. Pharmacol. 2003, 64:228-234.
28. Kempermann G., Jessberger S., Steiner B., Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 2004, 27:447-452.
29. Kishi N., Macklis J.D. Dissecting MECP2 function in the central nervous system. J. Child Neurol. 2005, 20:753-759.
30. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
31. Luo J. The role of GSK3beta in the development of the central nervous system. Front. Biol. 2012, 7:212-220.
32. Mari F., Azimonti S., Bertani I., Bolognese F., Colombo E., Caselli R., Scala E., Longo I., Grosso S., Pescucci C., Ariani F., Hayek G., Balestri P., Bergo A., Badaracco G., Zappella M., Broccoli V., Renieri A., Kilstrup-Nielsen C., Landsberger N. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum. Mol. Genet. 2005, 14:1935-1946.
33. O'Kusky J.R., Ye P., D'Ercole A.J. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J. Neurosci. 2000, 20:8435-8442.
34. Pan Y.W., Chan G.C., Kuo C.T., Storm D.R., Xia Z. Inhibition of adult neurogenesis by inducible and targeted deletion of ERK5 mitogen-activated protein kinase specifically in adult neurogenic regions impairs contextual fear extinction and remote fear memory. J. Neurosci. 2012, 32:6444-6455.
35. Pardo R., Andreolotti A.G., Ramos B., Picatoste F., Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J. Neurochem. 2003, 87:417-426.
36. Paul C.M., Magda G., Abel S. Spatial memory: theoretical basis and comparative review on experimental methods in rodents. Behav. Brain Res. 2009, 203:151-164.
37. Plath K., Mlynarczyk-Evans S., Nusinow D.A., Panning B. Xist RNA and the mechanism of X chromosome inactivation. Annu. Rev. Genet. 2002, 36:233-278.
38. Ricciardi S., Ungaro F., Hambrock M., Rademacher N., Stefanelli G., Brambilla D., Sessa A., Magagnotti C., Bachi A., Giarda E., Verpelli C., Kilstrup-Nielsen C., Sala C., Kalscheuer V.M., Broccoli V. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat. Cell Biol. 2012, 14:911-923.
39. Rusconi L., Salvatoni L., Giudici L., Bertani I., Kilstrup-Nielsen C., Broccoli V., Landsberger N. CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J. Biol. Chem. 2008, 283:30101-30111.
40. Sasaki T., Han F., Shioda N., Moriguchi S., Kasahara J., Ishiguro K., Fukunaga K. Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 2006, 1108:98-106.
41. Scala E., Ariani F., Mari F., Caselli R., Pescucci C., Longo I., Meloni I., Giachino D., Bruttini M., Hayek G., Zappella M., Renieri A. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J. Med. Genet. 2005, 42:103-107.
42. Sekiguchi M., Katayama S., Hatano N., Shigeri Y., Sueyoshi N., Kameshita I. Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch. Biochem. Biophys. 2013, 535:257-267.
43. Shors T.J., Miesegaes G., Beylin A., Zhao M., Rydel T., Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 2001, 410:372-376.
44. Smrt R.D., Eaves-Egenes J., Barkho B.Z., Santistevan N.J., Zhao C., Aimone J.B., Gage F.H., Zhao X. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol. Dis. 2007, 27:77-89.
45. Spittaels K., Van den Haute C., Van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van Lint J., Vandenheede J., Moechars D., Loos R., Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 2000, 275:41340-41349.
46. Spittaels K., Van den Haute C., Van Dorpe J., Terwel D., Vandezande K., Lasrado R., Bruynseels K., Irizarry M., Verhoye M., Van Lint J., Vandenheede J.R., Ashton D., Mercken M., Loos R., Hyman B., Van der Linden A., Geerts H., Van Leuven F. Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience 2002, 113:797-808.
47. Stuss D.P., Boyd J.D., Levin D.B., Delaney K.R. MeCP2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice. PLoS One 2012, 7:e31896.
48. Tao J., Van Esch H., Hagedorn-Greiwe M., Hoffmann K., Moser B., Raynaud M., Sperner J., Fryns J.P., Schwinger E., Gecz J., Ropers H.H., Kalscheuer V.M. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am. J. Hum. Genet. 2004, 75:1149-1154.
49. Trazzi S., Mitrugno V.M., Valli E., Fuchs C., Rizzi S., Guidi S., Perini G., Bartesaghi R., Ciani E. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum. Mol. Genet. 2011, 20:1560-1573.
50. Vadodaria K.C., Jessberger S. Functional neurogenesis in the adult hippocampus: then and now. Front. Neurosci. 2014, 10.3389/fnins.2014.00055.
51. Valli E., Trazzi S., Fuchs C., Erriquez D., Bartesaghi R., Perini G., Ciani E. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim. Biophys. Acta 2012, 1819:1173-1185.
52. van Praag H., Christie B.R., Sejnowski T.J., Gage F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13427-13431.
53. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J. Pharmacol. Sci. 2009, 110:14-28.
54. Wang I.T., Allen M., Goffin D., Zhu X., Fairless A.H., Brodkin E.S., Siegel S.J., Marsh E.D., Blendy J.A., Zhou Z. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:21516-21521.
55. Weaving L.S., Christodoulou J., Williamson S.L., Friend K.L., McKenzie O.L., Archer H., Evans J., Clarke A., Pelka G.J., Tam P.P., Watson C., Lahooti H., Ellaway C.J., Bennetts B., Leonard H., Gecz J. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am. J. Hum. Genet. 2004, 75:1079-1093.
56. Yoshimura T., Kawano Y., Arimura N., Kawabata S., Kikuchi A., Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005, 120:137-149.
57. Zhu Y.C., Li D., Wang L., Lu B., Zheng J., Zhao S.L., Zeng R., Xiong Z.Q. Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9118-9123.